Inside the Alethios Early-Stage Program: What Applicants Ask Most

As interest in the Alethios Early-Stage Program has grown, we’ve seen an exciting range of applicants—from startups building novel consumer health products to academic researchers pursuing new lines of inquiry. To address some of the most common questions that come up during the application process, Zoe Benham, who is leading the Early-Stage program at Alethios, shares answers and insights based on the projects and teams we’ve seen apply so far.

‍

Q: I’m interested in the Alethios Early-Stage Program. How does it work?
A:
When we say “early stage,” we’re referring to the stage of the research, not the maturity of the company or organization. The program is designed for startups, established organizations, and independent researchers who are exploring something important but are early in the evidence-generation process, and may not have had the funds to previously pursue it. The goal is to help teams design and run  credible human studies so they can generate data that informs product development, scientific strategy, or future research.

‍

Q: What does the application process look like?
A:
The application is intentionally simple. We’re not asking for pitch decks or fundraising materials. Instead, we want to understand who you are, what you’re building or studying, and what early-stage human study you want to run. The program is best suited for teams that are ready to launch a study in the near term and plan to use the results to inform real decisions.

‍

Q: What do you evaluate when reviewing applications?
A:
We primarily look at readiness and potential impact. Are you in a position to actually run a study soon? And will the results meaningfully move something forward—whether that’s product validation, scientific understanding, or future clinical planning? The application also includes optional questions about equity and access, which help us understand where lowering the barrier to research could have meaningful impact.

‍

Q: How selective is the program?
A:
Applications are reviewed on a rolling basis, and we keep the cohort intentionally small so we can support each project thoughtfully. Program pricing typically applies for up to twelve months and often covers one to two studies, depending on scope.

‍

Q: Why did Alethios create the Early-Stage Program?
A:
We created the program because we believe early-stage evidence generation shouldn’t be reserved only for teams with large budgets. Many important ideas never reach human research simply because the operational barriers are too high. This program is one way we lower those barriers and make credible human research more accessible.

‍

Q: Is the Alethios Early-Stage Program an accelerator? Do you take equity?
A:
No. The Early-Stage Program is not an accelerator, and Alethios does not take equity in exchange for participation. Instead, it’s a heavily discounted service designed to help early-stage teams run credible human studies when funding is limited. In some cases, small pilot studies or large observational studies can run for under $10K, allowing teams to generate initial human data before raising capital or scaling larger trials. While it isn’t structured as an accelerator, many teams find that running their first study becomes an important milestone in validating their product—something highlighted by companies like Kioga Bio, who prioritized early clinical validation to move from preclinical promise to human proof. You can read their full interview here.

‍

Q: Do you support individual research projects, such as dissertations or grant-funded studies?
A:
Yes. The program is open not only to startups and organizations but also to individual researchers, including those conducting dissertation research, academic projects, or grant-funded studies. If the project involves running a human study and aligns with the program’s goals, we’re happy to explore how Alethios can support it.

‍

Q: Do you support with publication?
A:
Yes. As part of our turn-key approach to study execution, we can connect teams with our network of principal investigators and academic collaborators who have supported study design, analysis, and publication in peer-reviewed journals. While publication timelines and requirements depend on the study itself, we aim to help ensure the research is structured in a way that can contribute meaningfully to the scientific literature.

‍

Q: Where can I learn more or apply?
A:
If you’re preparing to run an early-stage human study and want to explore the program, you can learn more and apply on the Alethios Early-Stage Program page.

‍